丙型肝炎病毒(hepatitis C virus,HCV)感染呈世界流行趋势,50%感染者转变为慢性肝炎,部分发展为肝硬化、肝细胞癌,给人类健康带来了极大危害。目前,没有疫苗研制成功,现有的HCV治疗药物普遍存在局限性,或者有一些药物没有发挥应有的作用。因此,开发新型、安全有效的抗HCV药物成为迫在眉睫的问题。NS5B蛋白是HCV复制的核心物质,具有RNA依赖的RNA聚合酶(RdRp)功能。研发有效的NS5B抑制剂,从而阻断病毒的复制,成为许多科研机构及制药公司的研究热点,有一些NS5B抑制剂已进入临床实验阶段。 Hepatitis C virus (HCV) infection is a worldwide epidemic, and 50% of the infected people turn to chronic hepatitis. Some of them develop cirrhosis and hepatocellular carcinoma and bring great harm to human health. Currently, there is a general lack of success in the development of vaccines, the prevalence of existing HCV therapies, or the failure of some drugs to do their job. Therefore, the development of new, safe and effective anti-HCV drugs has become an imminent problem. NS5B protein is the core substance of HCV replication, with RNA-dependent RNA polymerase (RdRp) function. R & D effective NS5B inhibitors, thereby blocking the virus replication has become the research focus of many research institutions and pharmaceutical companies, some NS5B inhibitors have entered the clinical trial phase.